Research into LSD came to a decided halt, largely because it had become synonymous with countercultural activities, hedonism and drug abuse. By the end of that colourful decade, LSD was considered in ...

A major Aussie university and ASX-listed company will deploy psychedelic drugs to treat binge-eating in a world-first clinical trial. Experimental healthcare company Tryptamine Therapeutics ...

While Tryptamine Therapeutics is a Stockhead advertiser, they did not sponsor this content. The post Tony’s Takeaway: Tryptamine Therapeutics and the psychedelic sector appeared first on Stockhead.

Tryptamine has kicked off its world-first Binge Eating Disorder trial with psilocin, with dosing around the corner and potential to ... Read More The post Tryptamine opens patient recruitment for ...

Tryptamine, a listed company with a market capitalisation of $43m, stresses the “confirmed reversibility” of TRP-8803 as a key selling point for the product.

Tillett has become a Tryptamine non-executive director. Carroll says Tryptamine is happy to stick with psilocybin, rather than dabble in MDMA, LSD or the ultra-trendy horse tranquilliser ketamine.